Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shionogi & Co ( (JP:4507) ) has shared an announcement.
Shionogi reported strong consolidated results for the fiscal year ended March 31, 2026, with revenue rising 14.0% to ¥499.7 billion and operating profit up 6.5% to ¥166.7 billion. Profit attributable to owners of the parent climbed 21.5% to ¥205.9 billion, lifting basic earnings per share to ¥241.11 on a post–stock-split basis, while comprehensive income surged 121.7%.
Total assets expanded sharply to ¥2.58 trillion from ¥1.54 trillion, driven by robust cash generation and financing, with cash and cash equivalents nearly doubling to ¥711.4 billion despite heavy investment outflows. The equity ratio attributable to owners of the parent decreased to 65.4% from 88.7%, reflecting balance sheet expansion, and Shionogi incorporated Torii Pharmaceutical as a consolidated subsidiary to strengthen its pharmaceutical platform.
The company maintained an aggressive shareholder-return stance, paying a total annual dividend of ¥71 per share for FY 2026 and guiding to ¥76 per share for FY 2027, implying a payout ratio just above 30%. For the year ending March 31, 2027, Shionogi forecasts a substantial 40.1% jump in revenue to ¥700 billion and a 32.0% rise in operating profit to ¥220 billion, even as it anticipates a modest decline in profit before tax, signaling continued investment and portfolio repositioning.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen3300.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange. The group focuses on research, development, manufacturing, and sales of prescription drugs, with a growing global footprint and a portfolio spanning infectious diseases and other therapeutic areas important to public health and healthcare systems.
Average Trading Volume: 2,741,658
Technical Sentiment Signal: Buy
Current Market Cap: Yen2794.3B
Find detailed analytics on 4507 stock on TipRanks’ Stock Analysis page.